Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $64,656.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,347 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $64,656.00. Following the completion of the sale, the senior vice president now directly owns 114,147 shares in the company, valued at approximately $5,479,056. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Paula Green also recently made the following trade(s):

• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total transaction of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total transaction of $13,941.18.

Twist Bioscience Stock Performance

Twist Bioscience stock traded down $2.77 during midday trading on Wednesday, hitting $42.49. 962,106 shares of the stock were exchanged, compared to its average volume of 941,048. The company has a 50 day moving average price of $43.86 and a two-hundred day moving average price of $45.95. Twist Bioscience Co. has a 1 year low of $18.59 and a 1 year high of $60.90.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the business. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience during the 3rd quarter valued at approximately $43,992,000. Point72 Asset Management L.P. boosted its stake in shares of Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after buying an additional 613,057 shares during the last quarter. Fred Alger Management LLC boosted its stake in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after buying an additional 575,080 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Twist Bioscience by 4.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock worth $23,717,000 after buying an additional 24,582 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in Twist Bioscience by 1.8% in the third quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock valued at $21,804,000 after acquiring an additional 8,529 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have commented on TWST shares. Robert W. Baird lifted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Barclays decreased their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.